Second-Generation Antidepressants for Treating Adult Depression—An Update
Specific Comparative Harms of Second-Generation Antidepressants for Adults With MDD (2 of 3)
The strength of evidence was moderate that trazodone was associated with a 16-percent higher incidence of somnolence than bupropion, fluoxetine, mirtazapine, paroxetine, and venlafaxine. High-strength evidence suggests that bupropion had fewer sexual side effects than escitalopram, fluoxetine, paroxetine, and sertraline. Moderate-strength evidence indicated that paroxetine had the highest rate of sexual side effects when compared with selective serotonin reuptake inhibitors as a class (16% vs. 6%). However, there was some low-strength evidence that sexual side effects may occur at different rates between men and women.
- Gartlehner G, Hansen RA, Morgan LC, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Comparative Effectiveness Review No. 46 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; December 2011. AHRQ Publication No. 12-EHC012-EF. Available at www.effectivehealthcare.ahrq.gov/secondgenantidep.cfm.
Your slide tray is being processed.